These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24080573)

  • 41. New insulins and insulin therapy.
    Danne T; Bolinder J
    Diabetes Technol Ther; 2013 Feb; 15 Suppl 1():S40-7. PubMed ID: 23441707
    [No Abstract]   [Full Text] [Related]  

  • 42. The evolution of insulin therapy in diabetes mellitus.
    Heile M; Schneider D
    J Fam Pract; 2012 May; 61(5 Suppl):S6-12. PubMed ID: 22577636
    [No Abstract]   [Full Text] [Related]  

  • 43. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.
    Bode B; Amin A
    Hosp Pract (1995); 2009 Dec; 37(1):7-21. PubMed ID: 20720383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolution of insulin development: focus on key parameters.
    Tibaldi JM
    Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The short-acting insulin analog Lispro (Humalog) in the treatment of diabetes--comparison of preprandial and postprandial administration and comparison with treatment using Humulin R].
    Perusicová J; Svehelka JM
    Vnitr Lek; 1998 Jul; 44(7):409-14. PubMed ID: 9748877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovative insulins--where do analogues fit?
    Phillips LK; Phillips PJ
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic treatment options for type 1 diabetes: what's new?
    Nally LM; Sherr JL; Van Name MA; Patel AD; Tamborlane WV
    Expert Rev Clin Pharmacol; 2019 May; 12(5):471-479. PubMed ID: 30892094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once daily insulin detemir in cystic fibrosis with insulin deficiency.
    Hameed S; Morton JR; Field PI; Belessis Y; Yoong T; Katz T; Woodhead HJ; Walker JL; Neville KA; Campbell TA; Jaffé A; Verge CF
    Arch Dis Child; 2012 May; 97(5):464-7. PubMed ID: 21493664
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The insulins.
    Bressler R; Galloway JA
    Ration Drug Ther; 1971 May; 5(5):1-6. PubMed ID: 5162936
    [No Abstract]   [Full Text] [Related]  

  • 51. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF; Curtis BH; Valentine WJ
    J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The future of basal insulin supplementation.
    Simon AC; DeVries JH
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S103-8. PubMed ID: 21568722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LY2605541--a preferential hepato-specific insulin analogue.
    Madsbad S
    Diabetes; 2014 Feb; 63(2):390-2. PubMed ID: 24464715
    [No Abstract]   [Full Text] [Related]  

  • 56. U-200 Humalog Insulin Now Available in United States.
    Chabanuk AJ
    Home Healthc Now; 2016 Feb; 34(2):102. PubMed ID: 26835809
    [No Abstract]   [Full Text] [Related]  

  • 57. The metabolic and mitogenic properties of basal insulin analogues.
    Tennagels N; Werner U
    Arch Physiol Biochem; 2013 Feb; 119(1):1-14. PubMed ID: 23373726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ultra-fast acting insulin analogues.
    Kalra S; Gupta Y
    Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(2):117-23. PubMed ID: 25022572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Premixed insulins. How do they compare with other insulin preparations?
    Hollander P
    Postgrad Med; 1991 Mar; 89(4):52-4, 57-8, 61. PubMed ID: 2000363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concentrated insulins: History and critical reappraisal.
    Heinemann L; Beals JM; Malone J; Anderson J; Jacobson JG; Sinha V; Corrigan SM
    J Diabetes; 2019 Apr; 11(4):292-300. PubMed ID: 30264527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.